Peroxisome Dysfunction Validation in Parkinson's Disease

Peroxisome Dysfunction Validation in PD

Experiment Overview

Hypothesis: Peroxisome dysfunction represents an upstream driver in PD pathogenesis, connecting lipid dysregulation, mitochondrial impairment, and alpha-synuclein aggregation.

Primary Objective: Validate peroxisome dysfunction in PD patient samples and test therapeutic interventions targeting peroxisome restoration.

Study Design: Multi-phase (preclinical + clinical)

Phase 1: Biomarker Discovery (Preclinical)

Specific Aims

Peroxisome Dysfunction Validation in PD

Experiment Overview

Hypothesis: Peroxisome dysfunction represents an upstream driver in PD pathogenesis, connecting lipid dysregulation, mitochondrial impairment, and alpha-synuclein aggregation.

Primary Objective: Validate peroxisome dysfunction in PD patient samples and test therapeutic interventions targeting peroxisome restoration.

Study Design: Multi-phase (preclinical + clinical)

Phase 1: Biomarker Discovery (Preclinical)

Specific Aims

Methods

| Parameter | Method | Samples |
|-----------|--------|---------|
| Peroxisome count | TOM20/PEX14 immunostaining | iPSC neurons |
| VLCFA levels | LC-MS/MS | Cell lysates, media |
| Plasmalogen levels | LC-MS/MS | Cell membranes |
| Catalase activity | Colorimetric assay | Cell lysates |
| Alpha-synuclein aggregation | pSer129 IF, ThT fluorescence | Neurons |
| Mitochondrial function | Seahorse XF | Neurons |

Interventions to Test

Phase 2: Clinical Biomarker Study

Study Design

• Type: Case-control biomarker study
• Cohort: 150 PD patients, 150 age-matched controls
• Primary Endpoints: VLCFA ratios, plasmalogen levels in plasma/CSF

Inclusion Criteria

• PD diagnosed by UK Brain Bank criteria
• Age 40-80 years
• Disease duration 1-10 years
• H&Y stage 1-3

Biomarker Measurements

| Biomarker | Method | Sample | Rationale |
|-----------|--------|--------|-----------|
| C26:0/C22:0 ratio | LC-MS/MS | Plasma, CSF | VLCFA accumulation |
| Plasmalogens (PC, PE) | LC-MS/MS | Plasma, CSF | Plasmalogen deficiency |
| Catalase activity | Colorimetric | Plasma | Antioxidant capacity |
| PEX gene expression | qPCR | PBMCs | Peroxisome biogenesis |

Phase 3: Therapeutic Trial

Trial Design

• Type: Randomized, double-blind, placebo-controlled
• Intervention: PPAR agonist (fenofibrate) 160mg daily
• Duration: 12 months
• Primary Endpoint: Change in MDS-UPDRS motor score

Rationale for Fenofibrate

• FDA-approved for dyslipidemia (safety established)
• Demonstrated peroxisome proliferation in preclinical models
• Blood-brain barrier penetration demonstrated
• Existing safety data in elderly patients

Sample Size Calculation

• Power: 80%
• Alpha: 0.05
• Expected effect: 4-point MDS-UPDRS improvement
• Dropout: 15%
• N: 120 per arm (240 total)

Study Timeline

| Phase | Duration | Milestone |
|-------|----------|-----------|
| Phase 1 | 6 months | iPSC characterization complete |
| Phase 2 | 12 months | Biomarker study complete |
| Phase 3 | 24 months | Clinical trial complete |

Success Criteria

Risks and Mitigations

| Risk | Mitigation |
|------|-------------|
| iPSC differentiation failure | Use established protocols, quality controls |
| Biomarker variability | Standardize sample collection, use internal standards |
| Insufficient drug penetration | Use fenofibrate, ensure BBB penetration data |
| Insufficient sample size | Power calculations, multicenter recruitment |

Budget Estimate

• Phase 1: $150,000
• Phase 2: $300,000
• Phase 3: $1,500,000
• Total: $1,950,000

References